C. Seyfried

发表

Delivery of nanoparticles to the brain detected by fluorescence microscopy.

G. Fricker, I. Reimold, D. Domke, 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

A pharmacological profile of the novel, peripherally‐selective k‐opioid receptor agonist, EMD 61753

H. M. Bender, R. Murray, J. Harting, 1994, British journal of pharmacology.

EMD 281014, a new selective serotonin 5-HT2A receptor antagonist.

C. Seyfried, G. Bartoszyk, H. Böttcher, 2003, European journal of pharmacology.

Effects of α‐Phenyl‐tert‐Butylnitrone and Selegiline on Hydroxyl Free Radicals in Rat Striatum Produced by Local Application of Glutamate

C. Seyfried, B. Ferger, K. Kuschinsky, 1998, Journal of neurochemistry.

Neurochemical profile of EMD 45609 (carmoxirole), a dopamine DA2-receptor agonist

H. Greiner, C. Seyfried, A. Haase, 1991, Naunyn-Schmiedeberg's Archives of Pharmacology.

High &bgr;1‐Selectivity and Favourable Pharmacokinetics as the Outstanding Properties of Bisoprolol

C. Schmitges, J. Harting, C. Seyfried, 1985, Journal of cardiovascular pharmacology.

SAR of novel biarylmethylamine dopamine D4 receptor ligands.

C. Seyfried, G. Bartoszyk, H. Böttcher, 1998, Bioorganic & medicinal chemistry letters.

The characterization of the dopaminergic profile of EMD 23,448, an indolyl-3-butylamine: Selective actions on presynaptic and supersensitive postsynaptic DA receptor populations

K. Fuxe, L. Agnati, F. Mascagni, 2005, Journal of Neural Transmission.

New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.

H. Wikström, B. Venhuis, S. Sundell, 1999, Journal of medicinal chemistry.

5-HT reuptake inhibitors with 5-HT(1B/1D) antagonistic activity: a new approach toward efficient antidepressants.

C. Seyfried, L. Matzen, L Matzen, 2000, Journal of medicinal chemistry.

Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.

J. Kehne, M. Athanasiou, C. Ashby, 2013, European journal of pharmacology.

Central and peripheral actions of the novel κ‐opioid receptor agonist, EMD 60400

R. Murray, J. Harting, C. Seyfried, 1994 .

Dopamine uptake inhibiting versus dopamine releasing properties of fencamfamine: an in vitro study.

C. Seyfried, 1983, Biochemical pharmacology.

Pharmacological profile of tazasubrate, a new cholesterol-lowering agent.

C. Seyfried, J. Obermaier, H. Diekmann, 1986, Atherosclerosis.

Pharmacological basis for antihypertensive therapy with a novel dopamine agonist.

C. Seyfried, I. Lues, K. Minck, 1992, European heart journal.

Synthesis and Structure−Activity Relationship in a Class of Indolebutylpiperazines as Dual 5-HT1A Receptor Agonists and Serotonin Reuptake Inhibitors

S. Anzali, T. Heinrich, H. Greiner, 2004 .

Demonstration of a new type of dopamine receptor agonist: an indolyl-3-butylamine. Actions at intact versus supersensitive dopamine receptors in the rat forebrain.

K. Fuxe, L. Agnati, C. Seyfried, 1982, Acta physiologica Scandinavica.

Sensitivity of dopamine D2 receptors following long-term treatment with roxindole.

C. Seyfried, G. Bartoszyk, 1994, European journal of pharmacology.

Biochemical and functional studies on EMD 49,980: a potent, selectively presynaptic D-2 dopamine agonist with actions on serotonin systems.

H. Greiner, C. Seyfried, A. Haase, 1989, European journal of pharmacology.

Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output

C. Seyfried, C. Amsterdam, 2014, Psychopharmacology.

Novel Dopamine Agonists of the Indolylbutylamine Type: Pre- Versus Postsynaptic Activity in Various in vivo and in vitro Models

H. Greiner, C. Seyfried, A. Haase, 1986 .

Sarizotan, a serotonin 5-HT1A receptor agonist and dopamine receptor ligand. 1. Neurochemical profile

H. Greiner, C. Seyfried, H. Russ, 2004, Journal of Neural Transmission.

Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity.

T. Heinrich, H. Greiner, K. Schiemann, 2004, Bioorganic & medicinal chemistry.

Neurochemical effects of pyritinol and their relevance for the treatment of brain function deficits in old age

C. Seyfried, 1989 .

Effects of sarizotan on the corticostriatal glutamate pathways

K. Fuxe, L. Ferraro, S. Tanganelli, 2005, Synapse.

Prodynorphin processing by rat CNS fractions and purified enzymes: Formation of Dynorphin A 1–8 by sulfhydryl-activated carboxypeptidase and peptidyl dipeptidase

M. Benuck, C. Seyfried, N. Marks, 1987, Neurochemistry International.

Synthesis and dopaminergic activity of some 3-(1,2,3,6-tetrahydro-1-pyridylalkyl)indoles. A novel conformational model to explain structure-activity relationships.

G. Barnickel, C. Seyfried, V. Eiermann, 1992, Journal of Medicinal Chemistry.

Synthesis and Dopaminergic Activity of Some 3-(1,2,3,6-Tetrahydro-1- pyridylalkyl)indoles. A Novel Conformational Model to Explain Structure-Activity Relationships.

G. Barnickel, C. Seyfried, V. Eiermann, 2010 .

Comparison of EMD 38362, (+)3-PPP, (−)3-PPP and BHT 920 in Pre- and Postsynaptic Models for D2-Activity: Discrepancies between in vivo and in vitro Results

C. Seyfried, 1988 .

Neurochemical Studies on the Mechanism of Action of Pyritinol

C. Seyfried, H. Greiner, A. Haase, 1988, Pharmacopsychiatry.